RiMO-301 / Coordination Pharma - LARVOL DELTA

Study of RiMO-301 and Radiotherapy With PD-1 Inhibitor for the Treatment of Head-Neck Cancer (clinicaltrials.gov) - P1/2 | N=16 | Recruiting | Sponsor: Coordination Pharmaceuticals, Inc. | Trial primary completion date: Jun 2026 ➔ Sep 2026

Trial primary completion date • Head and Neck Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma of Head and Neck

Phase I Study of RiMO-301 With Radiation in Advanced Tumors (clinicaltrials.gov) - P1 | N=32 | Completed | Sponsor: Coordination Pharmaceuticals, Inc. | Recruiting ➔ Completed | N=18 ➔ 32 | Trial completion date: Dec 2025 ➔ Jun 2025

Enrollment change • Trial completion • Trial completion date

Phase I Study of RiMO-301 With Radiation in Advanced Tumors (clinicaltrials.gov) - P1 | N=18 | Recruiting | Sponsor: Coordination Pharmaceuticals, Inc. | Trial completion date: Dec 2024 ➔ Dec 2025 | Trial primary completion date: Sep 2024 ➔ Sep 2025

Trial completion date • Trial primary completion date • Oncology

A phase 1 dose-escalation study of RiMO-301 with palliative radiation in advanced tumors. (ASCO 2023) - P1 | "RiMO-301 with or without pembrolizumab was well tolerated and demonstrated promising signs of efficacy in patients with advanced tumors when treated with concurrent palliative radiotherapy. The results support the use of RiMO-301 as a potential radio-enhancer and will prompt further phase 2 studies in the development of RiMO-301 for patients undergoing radiotherapy. Clinical trial information: NCT03444714."

Metastases • P1 data • Dermatitis • Dermatology • Hypotension • Immune Modulation • Immunology • Oncology • Pain • Xerostomia

Study of RiMO-301 and Radiotherapy With PD-1 Inhibitor for the Treatment of Head-Neck Cancer (clinicaltrials.gov) - P1/2 | N=16 | Recruiting | Sponsor: Coordination Pharmaceuticals, Inc. | Phase classification: P1b/2a ➔ P1/2

Metastases • Phase classification • Head and Neck Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma of Head and Neck

Phase I Study of RiMO-301 With Radiation in Advanced Tumors (clinicaltrials.gov) - P1 | N=18 | Recruiting | Sponsor: Coordination Pharmaceuticals, Inc. | Trial completion date: Dec 2022 ➔ Dec 2024 | Trial primary completion date: Sep 2022 ➔ Sep 2024

Metastases • Trial completion date • Trial primary completion date • Oncology